Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Lehners N, Ellert E, Xu J, Hillengass J, Leichsenring J, Stenzinger A, Goldschmidt H, Andrulis M, Raab MS.

Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443450. [Epub ahead of print]

PMID:
29616856
2.

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M, Raab MS.

Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

3.

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.

Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O'Dwyer ME.

Leukemia. 2017 Dec;31(12):2642-2651. doi: 10.1038/leu.2017.123. Epub 2017 Apr 25.

4.

Amyloid in bone marrow smears in systemic light-chain amyloidosis.

Kimmich C, Schönland S, Kräker S, Andrulis M, Ho AD, Mayer G, Dittrich T, Hundemer M, Hegenbart U.

Amyloid. 2017 Mar;24(1):52-59. doi: 10.1080/13506129.2017.1314959. Epub 2017 Apr 23.

PMID:
28434267
5.

Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre.

Giusca S, Mereles D, Ochs A, Buss S, André F, Seitz S, Riffel J, Fortner P, Andrulis M, Schönland S, Katus HA, Korosoglou G.

Int J Cardiovasc Imaging. 2017 Jun;33(6):879-888. doi: 10.1007/s10554-017-1065-7. Epub 2017 Jan 30.

PMID:
28138817
6.

[Predictive molecular pathological stratification of hematological neoplasms].

Andrulis M.

Pathologe. 2016 Nov;37(Suppl 2):210-216. Review. German.

PMID:
27613303
7.

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS.

Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25.

8.

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.

Radujkovic A, Dietrich S, Andrulis M, Benner A, Longerich T, Pellagatti A, Nanda K, Giese T, Germing U, Baldus S, Boultwood J, Ho AD, Dreger P, Luft T.

Int J Cancer. 2016 Sep 15;139(6):1402-13. doi: 10.1002/ijc.30181. Epub 2016 Jun 3.

9.

Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Lisenko K, Schönland SO, Jauch A, Andrulis M, Röcken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M.

Cancer Med. 2016 Jul;5(7):1464-72. doi: 10.1002/cam4.725. Epub 2016 Apr 25.

10.

Granulomatous mycosis fungoides, a rare subtype of cutaneous T-cell lymphoma.

Kogut M, Hadaschik E, Grabbe S, Andrulis M, Enk A, Hartschuh W.

JAAD Case Rep. 2015 Jul 31;1(5):298-302. doi: 10.1016/j.jdcr.2015.05.010. eCollection 2015 Sep. No abstract available.

11.

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T.

Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3.

12.

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Raab MS, Lehners N, Xu J, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M.

Blood. 2016 Apr 28;127(17):2155-7. doi: 10.1182/blood-2015-12-686782. Epub 2016 Feb 16. No abstract available.

13.

Individualized medicine and demographic change as determining workload factors in pathology: quo vadis?

Warth A, Stenzinger A, Andrulis M, Schlake W, Kempny G, Schirmacher P, Weichert W.

Virchows Arch. 2016 Jan;468(1):101-8. doi: 10.1007/s00428-015-1869-6. Epub 2015 Oct 24.

PMID:
26498186
14.

Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility.

Kreft A, Mottok A, Mesteri I, Cardona DM, Janin A, Kühl AA, Andrulis M, Brunner A, Shulman HM, Negri G, Tzankov A, Huber E; Gastrointestinal Pathology Group of the German-Austrian-Swiss GvHD Consortium.

Virchows Arch. 2015 Sep;467(3):255-63. doi: 10.1007/s00428-015-1803-y. Epub 2015 Jul 12.

PMID:
26164839
15.

Perianal hemorrhagic erythema.

Schirra A, Hartschuh W, Andrulis M, Enk A, Toberer F.

J Dtsch Dermatol Ges. 2015 Jul;13(7):707-9. doi: 10.1111/ddg.12666. Epub 2015 Jun 11. English, German. No abstract available.

PMID:
26095082
16.

Recurrent CDKN1B (p27) mutations in hairy cell leukemia.

Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T.

Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11.

17.

Gunpowder or Mycetoma?

Kriegsmann M, Harms A, Rickerts V, Andrulis M.

Int J Surg Pathol. 2015 Aug;23(5):373-4. doi: 10.1177/1066896915583395. Epub 2015 Apr 24. No abstract available.

PMID:
25911568
18.

De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.

Bartels S, Lehmann U, Büsche G, Schlue J, Hussein K, Debatin D, Karcher A, Andrulis M, Schirmacher P, Kreipe H.

Ann Hematol. 2015 Jul;94(7):1255-6. doi: 10.1007/s00277-015-2366-3. Epub 2015 Apr 14. No abstract available.

PMID:
25865944
19.

[Hairy cell leukemia].

Dietrich S, Andrulis M, Zenz T.

Internist (Berl). 2015 Apr;56(4):381-90. doi: 10.1007/s00108-014-3599-2. Review. German.

PMID:
25787322
20.

Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis.

Teichert M, Stumpf C, Booken N, Wobser M, Nashan D, Hallermann C, Mogler C, Müller CS, Becker JC, Moritz RK, Andrulis M, Nicolay JP, Goerdt S, Thomas M, Klemke CD, Augustin HG, Felcht M.

Exp Dermatol. 2015 Jun;24(6):424-9. doi: 10.1111/exd.12688. Epub 2015 Apr 16.

PMID:
25776770
21.

Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm.

Stenzinger A, Endris V, Pfarr N, Andrulis M, Jöhrens K, Klauschen F, Siebolts U, Wolf T, Koch PS, Schulz M, Hartschuh W, Goerdt S, Lennerz JK, Wickenhauser C, Klapper W, Anagnostopoulos I, Weichert W.

Oncotarget. 2014 Aug 15;5(15):6404-13.

22.

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.

Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C.

Genome Med. 2014 Apr 30;6(4):34. doi: 10.1186/gm551. eCollection 2014.

23.

Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology.

Andrulis M, Bäuerle T, Goldschmidt H, Delorme S, Landgren O, Schirmacher P, Hillengass J.

Eur J Radiol. 2014 Jun;83(6):970-974. doi: 10.1016/j.ejrad.2014.03.005. Epub 2014 Mar 22.

PMID:
24725673
24.

The glycome of normal and malignant plasma cells.

Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.

PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.

25.

Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.

Andrulis M, Ellert E, Mandel U, Clausen H, Lehners N, Raab MS, Goldschmidt H, Schwartz-Albiez R.

Histopathology. 2014 May;64(6):799-806. doi: 10.1111/his.12330. Epub 2014 Jan 21.

PMID:
24251368
26.

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer.

Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M, Mehrabi A, Hafezi M, Thelen A, Schirmacher P, Weichert W.

Br J Cancer. 2013 Nov 12;109(10):2665-74. doi: 10.1038/bjc.2013.610. Epub 2013 Oct 17.

27.

A complex secretory program orchestrated by the inflammasome controls paracrine senescence.

Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J.

Nat Cell Biol. 2013 Aug;15(8):978-90. doi: 10.1038/ncb2784. Epub 2013 Jun 16.

28.

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.

Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T.

J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. No abstract available.

PMID:
23690412
29.

Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.

Shah R, Stieltjes B, Andrulis M, Pfeiffer R, Sumkauskaite M, Delorme S, Schlemmer HP, Goldschmidt H, Landgren O, Hillengass J.

Ann Hematol. 2013 Nov;92(11):1553-7. doi: 10.1007/s00277-013-1786-1. Epub 2013 May 17.

PMID:
23680869
30.

Targeting the BRAF V600E mutation in multiple myeloma.

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.

Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23.

31.

[Hemoptysis in a patient with severe COPD and silicosis].

Sander KE, Sommer CM, Andrulis M, Reimer P, Kreuter M, Herth FJ, Heußel CP.

Med Klin Intensivmed Notfmed. 2013 Oct;108(7):592-4. doi: 10.1007/s00063-013-0228-0. Epub 2013 Mar 16. German. No abstract available.

PMID:
23494011
32.

The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.

Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC, Chatterjee M.

Br J Haematol. 2013 Feb;160(4):465-76. doi: 10.1111/bjh.12164. Epub 2012 Dec 18.

PMID:
23252346
33.

The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Chatterjee M, Andrulis M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H, Bargou RC.

Haematologica. 2013 Jul;98(7):1132-41. doi: 10.3324/haematol.2012.066175. Epub 2012 Oct 12.

34.

Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment.

Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M, Hegenbart U, Ho AD, Dreger P, Luft T.

Biol Blood Marrow Transplant. 2013 Jan;19(1):22-7. doi: 10.1016/j.bbmt.2012.09.018. Epub 2012 Oct 3.

35.

Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease.

Andrulis M, Dietrich S, Longerich T, Koschny R, Burian M, Schmitt-Gräf A, Schirmacher P, Ho AD, Dreger P, Luft T.

Haematologica. 2012 Nov;97(11):1674-7. doi: 10.3324/haematol.2011.061051. Epub 2012 Jun 11.

36.

Integrin-linked kinase is dispensable for multiple myeloma cell survival.

Steinbrunn T, Siegmund D, Andrulis M, Grella E, Kortüm M, Einsele H, Wajant H, Bargou RC, Stühmer T.

Leuk Res. 2012 Sep;36(9):1165-71. doi: 10.1016/j.leukres.2012.05.005. Epub 2012 Jun 1.

PMID:
22658851
37.

BRAF inhibition in refractory hairy-cell leukemia.

Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T.

N Engl J Med. 2012 May 24;366(21):2038-40. doi: 10.1056/NEJMc1202124. No abstract available.

38.

Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.

Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D.

Am J Surg Pathol. 2012 Dec;36(12):1796-800. doi: 10.1097/PAS.0b013e3182549b50.

PMID:
22531170
39.

Treatment of shiitake dermatitis by balneo PUVA therapy.

Scheiba N, Andrulis M, Helmbold P.

J Am Acad Dermatol. 2011 Aug;65(2):453-455. doi: 10.1016/j.jaad.2010.03.026. No abstract available.

PMID:
21763586
40.

Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.

Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, Mechtersheimer G, Petersen I, Paulus W, von Deimling A.

Histopathology. 2011 Jun;58(7):1167-72. doi: 10.1111/j.1365-2559.2011.03823.x.

PMID:
21707716
41.

Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology.

Hillengass J, Bäuerle T, Bartl R, Andrulis M, McClanahan F, Laun FB, Zechmann CM, Shah R, Wagner-Gund B, Simon D, Heiss C, Neben K, Ho AD, Schlemmer HP, Goldschmidt H, Delorme S, Stieltjes B.

Br J Haematol. 2011 Jun;153(6):721-8. doi: 10.1111/j.1365-2141.2011.08658.x. Epub 2011 Apr 22. Erratum in: Br J Haematol. 2011 Oct;155(2):281.

PMID:
21517815
42.

Charcot-Leyden crystals and bone marrow necrosis in acute myeloid leukemia.

Radujkovic A, Bellos F, Andrulis M, Ho AD, Hundemer M.

Eur J Haematol. 2011 May;86(5):451-2. doi: 10.1111/j.1600-0609.2011.01594.x. Epub 2011 Mar 30. No abstract available.

PMID:
21342270
43.

Discovered on gastrointestinal stromal tumor 1 (DOG1) is expressed in pancreatic centroacinar cells and in solid-pseudopapillary neoplasms--novel evidence for a histogenetic relationship.

Bergmann F, Andrulis M, Hartwig W, Penzel R, Gaida MM, Herpel E, Schirmacher P, Mechtersheimer G.

Hum Pathol. 2011 Jun;42(6):817-23. doi: 10.1016/j.humpath.2010.10.005. Epub 2011 Feb 4.

PMID:
21295818
44.

Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity.

Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, Meissner J, Krämer A, Ho AD, Dreger P.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1250-4. doi: 10.1016/j.bbmt.2010.12.706. Epub 2011 Jan 6.

45.

Expect the unexpected.

Macher-Goeppinger S, Longerich T, Hackert T, Andrulis M.

Int J Surg Pathol. 2010 Aug;18(4):301. doi: 10.1177/1066896910373097. No abstract available.

PMID:
20627955
46.

IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.

Andrulis M, Capper D, Meyer J, Penzel R, Hartmann C, Zentgraf H, von Deimling A.

Haematologica. 2010 Oct;95(10):1797-8. doi: 10.3324/haematol.2010.024430. Epub 2010 Jun 9. No abstract available.

47.

Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.

Andrulis M, Capper D, Luft T, Hartmann C, Zentgraf H, von Deimling A.

Leuk Res. 2010 Aug;34(8):1091-3. doi: 10.1016/j.leukres.2010.02.014. Epub 2010 Mar 12.

PMID:
20227112
48.

Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy.

Aulmann S, Waldburger N, Penzel R, Andrulis M, Schirmacher P, Sinn HP.

Hum Pathol. 2010 Apr;41(4):574-81. doi: 10.1016/j.humpath.2009.08.023. Epub 2009 Dec 11.

PMID:
20004947
49.

[Virtual microscopy in pathology teaching and postgraduate training (continuing education)].

Sinn HP, Andrulis M, Mogler C, Schirmacher P.

Pathologe. 2008 Nov;29 Suppl 2:255-8. doi: 10.1007/s00292-008-1097-9. German.

PMID:
18843489
50.

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.

Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC.

Blood. 2008 Oct 15;112(8):3403-11. doi: 10.1182/blood-2007-11-119362. Epub 2008 Jul 17.

Supplemental Content

Loading ...
Support Center